|Day Low/High||101.11 / 102.02|
|52 Wk Low/High||58.59 / 101.22|
Jim Cramer says it's going to take longer than most people think to reach a trade deal with China. He's got your game plan for next week.
Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the...
Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms of multiple sclerosis (RMS), at the 35 th Congress of...
Stocks finished higher Monday after President Donald Trump claims China contacted U.S. trade officials and said 'let's get back to' the negotiating table.
Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Jim Cramer's breaking down his thoughts on pajama trading, and the U.S.-China trade war.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Jim Cramer weighs in on the U.S.-China trade war and Amgen.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
We will sell out of one of the most expensive stocks in the portfolio (Shopify) with no yield and redeploy that capital into one of the cheapest in the portfolio with a solid yield (Viacom).
Amgen will acquire the global rights to Celgene's oral psoriasis treatment Otezla for $13.4 billion in cash, paving the way for Bristol Myers-Squibb to compete its acquisition of Celgene.
Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World
Jefferies raises its price target for AMGN and judgement day looms for JNJ; here's our take on the health of both companies.
Celgene Corporation (NASDAQ: CELG) today announced the U.S.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
These stocks and sectors are safe havens, and may even be opportunities.
Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.
Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.
Celgene Corporation (NASDAQ: CELG) reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 million in the second quarter of 2018.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb's pending acquisition of Celgene Corporation (NASDAQ:CELG).
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.